Aldapt M, Wang Y-H, Shah KJ, El Kettani M, Foran J, Kharfan-Dabaja M, Murthy H, Al-Kali A, Shah MV, Alkhateeb H, Saliba AN, Hogan W, Yi CA, Sproat L, Punwani N, Khera N, Palmer J, Litzow M, Tefferi A, Gangat N, Patnaik MM, Badar T. Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i&gt;-mutated myelodysplastic syndromes. haematol [Internet]. 2020Sep.10 [cited 2026Jan.14];. Available from: https://haematologica.org/article/view/13087